The standard systemic treatments for advanced HCC are combination therapies with immune checkpoint inhibitors and vascular endothelial growth factor (VEGF) antibodies or monotherapies of tyrosine kinase inhibitors. This evidence concerns the gene VEGFA and hepatocellular carcinoma.